Immatics N.V

NASDAQ:IMTX   2:33:21 PM EDT
9.50
0.00 (0.00%)
Products

Immatics Presents Comprehensive Preclinical Data Set For TCR Bispecific Candidate IMA402

Published: 09/10/2022 09:19 GMT
Immatics N.V (IMTX) - Immatics Presents Comprehensive Preclinical Data Set for Tcr Bispecific Candidate Ima402 Targeting Prame at European Society for Medical Oncology (esmo) Congress 2022.
Immatics- Ima402 Demonstrated Enhanced Anti-tumor Activity in Vivo,reduced T Cell Engager-associated Toxicities.
Phase 1/2 Clinical Trial on Track to Start in 2023; Submission of the Cta/ind1 Application is Planned for 2q 2023.